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Abstract
Intussusceptive angiogenesis (IA) known also as splitting angiogenesis is a recently 
described mechanism of vascular growth alternative to sprouting. It plays an essential 
role in the vascular remodeling and adaptation of vessels during normal and pathological 
angiogenesis. It is an “escape” mechanism during and after irradiation and anti-VEGF 
therapy, both inducing angiogenic switch from sprouting to IA by formation of multiple 
transluminal tissue pillars. Our recently published data revealed the significant induction 
of IA after inhibition of Notch signaling associated with an increased capillary density 
by more than 50%. The induced IA was accompanied by detachment of pericytes from 
basement membrane, increased vessel permeability and recruitment of mononuclear cells 
toward the pillars; the process was dramatically enhanced after injection of bone marrow-
derived mononuclear cells. The extravasation of mononuclear cells with eventual bone 
marrow origin was associated with upregulation of chemotaxis factors SDF-1 and CXCR4. 
In addition, SDF-1 expression was upregulated in the endothelium of liver sinusoids in 
Notch1 knockout mouse, together with vascular remodeling by intussusception. In this 
chapter, we discuss this important mechanism of angiogenesis, as well as the role of Notch 
signaling, SDF-1 signaling and mononuclear cells in the complex process of angiogenesis.
Keywords: intussusceptive angiogenesis, Notch signaling, mononuclear cells, SDF-1/
CXCR4 signaling
1. Introduction: intussusceptive angiogenesis
Angiogenesis is essential for normal embryonic development and reproductive cycle and 
plays a key role in pathological conditions such as tumor growth and ischemic cardiovascular 
diseases. This is a complex process involving essential signaling pathways for instance VEGF, 
bFGF, and Notch, etc., in vasculature, as well as additional players such as bone marrow-
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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derived endothelial progenitor cells. Better understanding the role of the different pathways 
and the crosstalk between different cells during angiogenesis is a crucial factor for developing 
more effective proangiogenic and antiangiogenic anticancer therapy.
Angiogenesis involves the formation of new blood vessels from a preexisting vascular plexus, 
and based on morphological characteristics two main distinct processes have been identified, 
sprouting and intussusceptive angiogenesis (IA) [1–3]. Sprouting angiogenesis has been well 
described since more than 150 years. Recent publications indicated that sprouting involves 
tip/stalk cell differentiation and crosstalk process which is tightly controlled by the VEGF and 
Notch/Dll4 signaling pathway [4, 5]. Intussusceptive angiogenesis (IA) is a particular form of 
vascular growth and remodeling in which endothelial cells make invagination intraluminally 
instead of extraluminally like it is in the sprouting. The cells form protrusions toward the 
vessel lumen resulting in the appearance of transluminal endothelial pillars–the hallmarks of 
intussusception. The arising pillars afterward are successively reshaped and fused and lead 
to “splitting” of the preexisting vessel in two segments, thus doing remodeling and organiza-
tion of the vasculature. The effect is the formation of hierarchically organized vessels with 
supplying and draining function, pruning of arteries, and veins, and finally development 
of the primitive capillary plexuses into the functional vascular system. IA is a process with 
several consecutive steps, including intussusceptive microvascular growth, intussusceptive 
arborization, and intussusceptive remodeling [2, 3, 6, 7]. These processes end in the forma-
tion of mature vascular networks. In comparison to sprouting angiogenesis, intussusception 
is a quite fast process, enabling the vascular system to swift adaptation in unfavorable con-
ditions. IA has been identified as the leading mode of vascular growth in animal models of 
liver regeneration and in alveolar angiogenesis following pneumonectomy. Intussusception 
appears to be predominant above sprouting in extra-embryonic vasculatures including the 
vitelline circulation as well [8-10]. The intensive work of our group in the past few decades 
clearly documented the morphological features of this specific angiogenic mode and dem-
onstrated its definite presence during development and tumorigenesis as a complementary 
to sprouting vessel growth. Surprisingly, the cellular and molecular regulation of intussus-
ception is less well known but recent evidence suggests that it might involve a component 
regulated by blood flow and Notch signaling [7, 9]. We provided with evidence showing that 
Notch regulates intussusception involving interaction with circulating mononuclear cells in 
developing vascular networks [11].
Intussusceptive angiogenesis (IA) is a well-documented and widely spread mode of angiogen-
esis, occurring during both normal development and in pathological conditions. In contrast to 
sprouting angiogenesis, whereby abluminal sprouts outgrow and subsequently merge with 
the existing capillaries, intussusceptive angiogenesis is elaborated by intraluminal growth of 
endothelial cell processes. The last protrude from the opposing sides of the vessel wall and 
form transluminal tissue pillar, representing endothelial bilayer, which is afterward perforated 
and stabilized from outside by collagen bindles. Repetitive formation of pillars and their sub-
sequent fusion leads to the splitting of vessels and vascular expansion. Another way of intus-
susceptive angiogenesis is to increase the size of the pillar and form meshes, thus splitting the 
vessel. Intussusceptive angiogenesis is a process linked to both blood vessel replication and 
remodeling in development. It is present within the regions of increased vascular density in 
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alveolar angiogenesis during compensatory growth after pneumonectomy in a murine model 
of postpneumonectomy lung growth [8]. The remodeling of the retiform meshworks in the 
avian lung was essentially accomplished by intussusceptive angiogenesis as well [12].
In addition to its developmental role, intussusceptive angiogenesis is well documented as a 
mechanism of vascular adaptation in response to different environmental stimuli. In the adult 
mouse retina, it was reported as a main adaptive mechanism to chronic systemic hypoxia 
[13]. These investigations contribute to our understanding of hypoxia-induced angiogen-
esis and microvascular remodeling. The process of intraluminal division participates in the 
inflammation-induced neovascularization associated with chemically induced murine colitis 
[14]. Scanning electron microscopy (SEM) of vascular corrosion casts demonstrated replication 
of the mucosal plexus without significant evidence of sprouting angiogenesis, whereas pillar 
formation and septation were present within days of the onset of inflammation. The authors 
conclude that intussusceptive angiogenesis is a fundamental mechanism of microvascular 
adaptation to prolonged inflammation. It is also a mechanism of compensation for vascular 
growth. In a capillary regression model of inflamed murine corneas, the abrupt termination 
of capillary sprouting is followed by an intussusceptive response [15]. The capillary repair 
during kidney recovery in Thy1.1 nephritis was done by intussusceptive angiogenesis [16]. 
Inhibitors of angiogenesis and radiation induce compensatory changes in the tumor vascula-
ture both during and after cessation of treatment. There is a switch from sprouting to intus-
susceptive angiogenesis, which may be an adaptive response of tumor vasculature to cancer 
therapy that allows the vasculature to maintain its functional properties [17–19]. Potential 
candidates for molecular targeting of this angioadaptive mechanism are yet to be elucidated 
in order to improve the currently poor efficacy of contemporary antiangiogenic therapies. 
Important is the involvement of intussusceptive angiogenesis in pathological conditions. 
Vascular remodeling of the hepatic sinusoidal microvasculature in the course of liver nodu-
lar hyperplasia is a result of intussusceptive growth [9]. This angiogenic mode is widely 
involved in tumor development. By using electron and confocal microscopy, Paku et al. 
[20] observed intraluminal nascent pillars that contain a collagen bundle covered by endo-
thelial cells (ECs) in the vasculature of experimental tumors. Tumor angiogenesis in liver 
metastasis from colon carcinoma is a controversial subject. Ceauşu et al. [21] concluded 
that in liver metastasis principal mechanism of neovascularization formation is based on 
intussusception. In metastatic tumors of the brain there was intussusceptive angiogenesis, 
whereby the fibrosarcoma cells were attached to the vessel, filled the developing pillars, 
and caused lumen splitting [22]. Branching angiogenesis was not observed either in the 
tumors or in control cerebral wounds. These data suggest that sprouting angiogenesis is 
not needed for the incipient growth of cerebral metastases and that tumor growth in this 
model is a result of incorporation of host vessels. Prolactin was found to directly stimulate 
angiogenesis in breast cancer progression, enhancing vessel density and the tortuosity of 
the vasculature by pillar formation, which are hallmarks of intussusceptive angiogenesis 
[23]. It is a preferred mode of angiogenesis in oral squamous cell carcinoma [24] and in 
hepatocellular carcinoma [25, 26].
Despite this variety of intussusceptive angiogenic roles, most of the current research is 
focused on the mechanism of sprouting angiogenesis because this mechanism was first 
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described and most existing experimental models are related to sprouting angiogen-
esis. Consequently, the mechanism of intussusceptive angiogenesis is often overlooked 
in angiogenesis research [27]. Intussusception is an alternative to the sprouting mode of 
angiogenesis. The advantage of this mechanism of vascular growth is that blood vessels are 
generated more rapidly and the capillaries thereby formed are less leaky [1]. The regula-
tion of intussusceptive angiogenesis is still to be elucidated. There are some hypotheses 
about the possible drivers of intussusception. In the sprouting type of angiogenesis related 
to hypoxia, there is no blood flow in the rising capillary sprout. In contrast, it has been 
shown that an increase of wall shear stress initiates the splitting type of angiogenesis in 
skeletal muscle [7]. Inflammation-associated intussusceptive angiogenesis in adult mice 
was associated with vessel angle remodeling and the morphometry of the vessel angles 
suggests the influence of blood flow on the location and orientation of remodeled vessels 
[28]. Regarding molecular regulation, very little is known for the molecular factors with 
potential significance. Application of the essential angiogenic factors VEGF and bFGF in 
an arteriovenous loop model demonstrated advanced neovascularization in the phase of 
remodeling by a higher incidence of intussusception, compared to control without these 
factors [29]. It was shown in Ewing sarcomas and rhabdomyosarcomas that treatment sup-
pressing IGF-1 signaling decreases intussusceptive angiogenesis [30].
The main factors for maturation and hierarchical organization of vessels, especially arterial 
ones, are Notch, angiopoietin, and ephrin. In addition, it was shown that SDF-1 (CXCL12) is 
a crucial maturation factor in coronary arterial vasculature, since its mutants have immature 
capillary plexus and selective failure in arterial maturation, particularly with the onset of 
coronary perfusion [31].
Our preliminary results suggest that intussusception is most probably synchronized by che-
mokine factors since intussusceptive growth was associated with the recruitment of mono-
nuclear cells [11]. After injection of bone marrow-derived mononuclear cells, we observed 
robust induction of intussusception in Notch inhibited samples. Notably, the chemotactic 
factors SDF-1/CXCR4 were upregulated only due to the Notch inhibition. Our hypothesis 
is that Notch inhibition disturbed vessel stability and led to pericyte detachment followed 
by extravasation of mononuclear cells due to the activation of the SDF-1/CXCR4 axis. The 
stromal cell-derived factor SDF-1 is binding to its receptor CXCR4 and directs migration of 
progenitor cells into the appropriate sites. The mononuclear cells contributed to the formation 
of transluminal pillars with sustained IA resulting in a dense vascular plexus.
2. Notch signaling and intussusceptive angiogenesis
The crucial role for Notch/DLL4 signaling in regulating vascular development was established 
based on findings from the analysis of targeted mouse and zebrafish mutants in Notch path-
way components [32–35]. The common characteristics of the most of these mutants were the 
absence of angiogenic vascular remodeling, lack of arterial markers, and arteriovenous malfor-
mations. Mouse embryos deficient for Notch-ligand Jagged1 (Jag1), Notch1, Notch1/Notch4, 
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or the presenilins, die between E9.5 and 10.5 and have severely disorganized vasculature [36]. 
Transgenic mice with inappropriate activation of Notch4 also display similar defects and die, 
which suggests that the appropriate Notch expression pattern (in levels, sites, and time) is 
critical for embryonic vascular development [37]. It was found out that Notch1, Notch2, and 
Notch4 are expressed predominantly in endothelial cells of aorta and arteries, whereas Notch3 
was in VSMCs of arteries [38].
Recently, we have established that Notch inhibition disturbs vessel stability and induces 
intussusceptive neo-angiogenesis, triggering in this way the augmentation of the capillary 
plexus but without the accompanying vascular maturation and remodeling. It was associ-
ated with extravasation of mononuclear cells of bone marrow origin possibly by upregulation 
SDF-1/CXCR4 chemotactic factors.
Using the chick area vasculosa (and inhibiting Notch signaling by the γ-secretase inhibitor–GSI) 
and a mouse model of Notch inhibition (MxCre Notch1lox/lox mice), we have demonstrated that 
in already existing vascular beds disruption of Notch-signaling triggers rapid augmentation of 
the vasculature predominantly by intussusceptive angiogenesis [11]. The process is initiated by 
pericyte detachment followed by extravasation of mononuclear cells (Figure 1). The latter cells 
contributed to formation of transluminal pillars [11]. The sustained IA results in a very dense 
vascular plexus but without the usual concomitant vascular remodeling or maturation.
The genetic approach in mice substantiated by pharmacological studies for developing vascu-
lar networks in chicken embryo enabled us to show that Notch is critical for intussusceptive 
angiogenesis. In both models we demonstrated considerable changes in vascular morphogen-
esis, resulting in massive induction of intussusception. Inhibition of DLL4/Notch signaling 
by novel therapeutic antibody against DLL4, performed in a recently published study [39], 
was associated with threefold increase in vessel density and stimulation of vessel formation. 
At the same time, marked reduction in the number of smooth muscle actin (SMA)-positive 
mural cells was noted. Two-dimensional appearance of the blood vessels in the described 
phenotype highly resembles the data in our chicken and mouse models. Similar phenotypes 
were observed after Notch inhibition during developmental angiogenesis, in skeletal muscle 
and in tumor models, showing increased vessel number and increased vascular permeability 
[40–43]. The terminology for the resultant vascular pattern, used by authors in these studies, 
was “abnormal vessels” or “excessive, nonproductive angiogenesis.” They focused mainly 
on the front of sprouting invasion after blocking Notch signaling, thus describing only newly 
developing, nonperfused vasculature. Along with the observed significantly increased ves-
sel density under Notch inhibition, there was evidently demonstrated reduced mural cell 
coverage. The authors reported positivity for endothelial markers in the endothelial protru-
sions toward the vessel lumen and in the intraluminal vessel occlusions [44], but they did not 
attribute this phenomenon to the induced intussusceptive angiogenesis. The detailed investi-
gation of this vascular pattern behind the sprouting mode of vessels invasion demonstrated 
that Notch inhibition led to IA in already perfused vascular bed and this is a complementary 
mechanism of angiogenesis. In fact, the authors above mentioned here nicely described the 
characteristic features of intussusceptive microvascular growth even though they did not use 
the terminology.
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3. Role of mononuclear cells in angiogenesis
To test the role of bone marrow cells in the process of intussusception, in our previous study 
we isolated bone marrow mononuclear cells (BMMNC) from E14 chicken embryos and/or 
4-week-old mice, labeled them with a fluorescent cell tracker (TAMRA) and injected them into 
the Notch inhibited (by GSI) and control samples 3 hours prior to time point 24 hours at which 
Figure 1. Inhibition of Notch signaling led to detachment of pericytes from endothelium (indicated by arrows), as it 
is shown at different time points after the application of GSI; it is followed by the extravasation of mononuclear cells 
(Mo); L–vessel lumen.
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time the samples were visualized by FITC injection [11]. About 3–4 hours after BMMNCs 
injection, we observed a significant induction of intussusception in the GSI-treated area as we 
detected high increase in the pillar number (4.2-fold) in inhibited samples as compared to con-
trols. Injection of BMMNCs in the area vasculosa after Notch inhibition dramatically induced 
increase in microvascular density by onset of IA. Microvascular area density increases sig-
nificantly by 80% after injection of BMD cells in Notch-inhibited samples in comparison with 
injection of BMD cells in PBS. Pillar density demonstrated dramatic augmentation by 63% 
compared to the Notch inhibition alone and more than 400% as compared to PBS.
We have largely expanded our knowledge about the role of bone marrow-derived cells in 
stimulating angiogenesis after their discovery in 1997 [45] and now their capability to pro-
mote vessel formation is intensively investigated. There are large clinical perspectives for 
their use in many diseases, connected to angiogenesis.
With the tendency of aging, the elderly will account for a great part of population world wide. 
This aging will be accompanied by chronic vascular dementia, due to chronic cerebral hypo-
perfusion. Cellular therapy is an emerging investigational approach for cerebral ischemia. The 
most attractive source for such therapy is bone marrow-derived mononuclear cells (BMMNC), 
since they consist of different types of stem cells. Several independent studies report the sig-
nificant effects of BMMNC in ischemic repair after acute and chronic ischemic disorders. The 
intravenous infusion of BMMNC into rat brain ischemic model reduced neurologic impair-
ments, increased angiogenesis and cognitive function in rodent [46]. Mononuclear cells from 
blood have therapeutic potential as well. The neuroprotective potential of CD34+ human cord 
blood cells was demonstrated in regard to Parkinson's disease [47]. These cells did not dif-
ferentiate into neural phenotypes, but they rather exerted their effect by stimulating the pro-
duction of new neuroblasts and angiogenesis. CD34+ stem cell therapy was enrolled in 2011 
for 37 patients with longstanding dilated cardiomyopathy (DCM) by cell mobilization with 
colony stimulating factor (G-SCF) and apheresis collection [48]. Clinical response and stem 
cells retention were evaluated. About half of the patients (51%) were responders to the stem 
cells therapy, whereby the clinical response was predefined as an increase in left ventricle 
ejection fraction (LVEF) of >5% in 3 months. Looking for biomarkers, which can be instru-
mental in prediction which patients will be responders, the authors suggested some baseline 
factors, positively associated with both clinical response and retention, such as G-CSF, SDF-1, 
LIF, MCP-1, and MCP-3. The most recent study described the significant effect of human cord 
blood mononuclear cells (CB-MNCs) injection for cardiac repair in ischemic heart disease, 
mainly by promotion of angiogenesis in the infarcted region [49].
The mechanisms of action for mononuclear cells in angiogenesis have been intensively stud-
ied. The domain comes to be multifaceted and contradictory data were sometimes arising.
First, it was proposed and evidence was provided that myeloid cells can turn into endothelial 
cells in hypoxic tissue demand. Asahara et al. reported that purified CD34+ hematopoietic 
progenitor cells in adults can differentiate ex vivo to an endothelial phenotype [45]. The cells 
were at the same time positive for VEGFR2, a specific endothelial marker and they were 
named endothelial progenitor cells (EPC). Thus, EPC expresses both hematopoietic stem cell 
and endothelial cell markers on their surface [50]. The intensive studies in the past few years 
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allowed distinguishing subpopulations of mononuclear cells existing in the adult bone mar-
row and circulating in peripheral blood which support angiogenesis without incorporating 
permanently into the newly formed vessel–circulating angiogenic cells (CAC) [51]. Currently, 
bone marrow-derived (BMD) cellular populations with angiogenic properties are classi-
fied according to their phenotypic markers in the following groups: (i) EPC, which express 
VEGFR2, Tie2, CXCR4, CD31, CD34, CD133 (for immature progenitor cells) and they are 
negative for CD14; (ii) monocytes, which express CD14 and have different subclasses such 
as positive for Tie2, CXCR4, VEGFR2, or VEGFR1; and (iii) macrophages, mostly positive for 
CXCR4 and VEGFR1 [52].
Several clinical studies have shown a correlation between a high number of tumor-associated 
macrophages and increased microvessel density, suggesting that these cells might promote 
tumor angiogenesis, particularly due to production of proangiogenic and angiogenesis modu-
lating factors [53]. A number of functional in vitro and in vivo studies demonstrate that tumors 
stimulate neutrophils to promote angiogenesis and immunosuppression, as well as migration, 
invasion, and metastasis of the tumor cells [54]. In inflammation, the SDF-1/CXCR4 signaling 
pathway plays an important role in the modulation of neutrophil activity, not only by promot-
ing chemotaxis but also by suppressing cell death [55]. Although limited, there is evidence to 
suggest that tumor-infiltrating eosinophils can influence angiogenesis [53]. Freshly isolated 
human blood eosinophils or supernatants from cultured eosinophils induce endothelial cell 
proliferation in vitro and angiogenesis in the rat aortic ring assay, suggesting that eosinophils 
can directly influence angiogenesis. The high number of mast cells (MC) has been observed in 
various tumors where increased MC density positively correlates with increased microvessel 
density [53]. Dendritic cells (DC) promote tumor angiogenesis both by their secretion of pro-
angiogenic cytokines (vascular endothelial growth factor (VEGF), interleukin (IL)-8, tumor 
necrosis factor (TNF)-alpha) and their ability to serve as a local supply of endothelial progeni-
tors [56]. Natural killer (NK) cells control both local tumor growth and metastasis and partici-
pate in cancer elimination by inhibiting cellular proliferation and angiogenesis [57]. T helper 
(Th) cell-mediated immunity has traditionally been viewed as favoring tumor growth, both 
by promoting angiogenesis and by inhibiting cell-mediated immunity and subsequent tumor 
cell killing, there are also many studies demonstrating the antitumor activity of CD4+ Th2 
cells, particularly in their collaboration with tumor-infiltrating eosinophils or due to direct 
antiangiogenic effects of IL-4 [58]. T regulatory cells (Tregs) are potent immunosuppressive 
cells that promote progression of cancer through their ability to limit antitumor immunity 
and promote angiogenesis. The accumulation of Tregs in tumors correlates with biomarkers 
of accelerated angiogenesis such as VEGF overexpression and increased microvessel density, 
providing clinical cues for an association between Tregs and angiogenesis [59].
Mononuclear cells, derived from bone marrow or umbilical cord, yielded in culture two types 
of cells with angiogenic properties, distinguished by morphology–late endothelial  progenitor 
cells (EPC) and mesenchymal stem cells (MSC). Quantitative PCR analyses revealed high 
expression levels of Ang-1, FGF-2, SDF1α, and VEGF-A in the MSC, whereas late EPC had 
higher expression of PDGF-B, PlGF, KDR, CD31, VE-cadherin, and Ang-2 [60]. After trans-
plantation of EPC and MSC in the ischemic hearts, mRNA levels of Ang-1, FGF2, SDF1α, and 
IGF-1 were significantly increased in tissues collected from the peri-infarct zones; notably 
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the upregulated factors were the same in both cell types transplanted. The data demonstrate 
that these cells upregulate a number of paracrine factors connected to angiogenesis and cell 
survival during the critical period of heart repair.
Although the role of bone marrow and peripheral blood mononuclear cells in neovasculariza-
tion has been convincingly shown, the question remains: how do these cells improve neovas-
cularization? The discovery that mononuclear cells can home to sites of hypoxia and enhance 
neoangiogenesis has faced the possibility for using the isolated hematopoietic stem cells or 
EPC for therapeutic vasculogenesis [61]. Remarkably, infusion of terminally differentiated 
mature endothelial cells did not improve neovascularization [62, 63] suggesting that a not-
yet-defined functional characteristic (e.g., chemokine or integrin receptors mediating hom-
ing) is essential for EPC-mediated vascular augmentation after ischemia [64]. Monocytic cells 
may play a crucial role also in collateral growth by adherence to the vascular wall during 
both arteriogenesis and tumor angiogenesis [53]. These data suggest that monocytic cells are 
necessary for arteriogenesis and possibly neovascularization. For therapeutic application, the 
local enhancement of monocyte recruitment might be better suited than systemic infusion of 
monocytic cells, which only leads to a relatively minor increase in the number of circulating 
monocytes. During endothelial repair after vascular injury and during tumor angiogenesis 
BMMNC do not seem to be involved in reendothelialization stressing rather their supportive 
role over trans-differentiation [65, 66].
The hypothesis for endothelial trans-differentiation of EPC and MSC was tested in the experi-
ment with CM-Dil-labeled (red fluorescent dye) mononuclear cells and subsequent transplan-
tation in infarcted hearts. Interestingly, both EPC and MSC were detected in the pericytic or 
perivascular areas with minimal and negligible endothelial trans-differentiation effects (<1%). 
It was suggested that these cells function mainly by paracrine action and vessel stabiliza-
tion in the perivascular area. The efficiency of neovascularization therefore may not solely 
be attributable to the incorporation of these cells in newly formed vessels, but may also be 
influenced by the release of proangiogenic factors in a paracrine manner [67]. It was recently 
shown that secreting factors from peripheral blood mononuclear cells enhance neoangiogen-
esis [68]. The capacity of EPC to physically contribute to vessel-like structures may contrib-
ute to their potent capacity to improve neovascularization as well [69]. Further studies are 
in demand to be designed to elucidate the contribution of physical incorporation, paracrine 
effects and possible effects on vessel remodeling and facilitating vessel branching in EPC-
mediated improvement of neovascularization. Likely, paracrine effects contribute in addition 
to the physical incorporation of EPC into newly formed capillaries. The influence of the incor-
poration of a rather small number of circulating cells on remodeling and vessel maturation 
has to be further elucidated.
Only recently the bone marrow-derived monocytes have been related to VEGF-independent 
angiogenesis [70]. An open question is what drives BMD and PBM cells recruitment to the 
sites of angiogenesis? Ischemia is believed to upregulate VEGF or SDF-1 [71], which in turn 
are released to the circulation and induce mobilization of progenitor cells from the bone mar-
row via a MMP-9–dependent mechanism [72, 73]. Indeed, SDF-1 has been proven to stim-
ulate recruitment of progenitor cells to the ischemic tissue [74]. SDF-1 protein levels were 
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increased during the first day after induction of myocardial infarction [75]. Moreover, over-
expression of SDF-1 augmented stem cell homing and incorporation into ischemic tissues [74, 
75]. Interestingly, hematopoietic stem cells were shown to be exquisitely sensitive to SDF-1 
and did not react to G-CSF or other chemokines (e.g., IL-8 and RANTES) [76]. The migratory 
capacity of EPC or bone marrow cells toward VEGF and SDF-1, respectively, determined the 
functional improvement of patients after stem cell therapy [77].
SDF-1/CXCR4 axis is crucial in the homing mechanisms of hematopoietic cells and the metas-
tasis of solid tumors. In the past few years, numerous studies have focused on studying the 
role of this signaling in angiogenesis and proved its angiogenic activity in organ repair and 
tumor development. However, the precise mechanisms by which SDF-1 exerts its proangio-
genic effects are not fully elucidated. Since it is supposed to be an angiogenic growth factor, 
it is a good candidate for pro- and antiangiogenic therapy. It was reported that transient dis-
ruption of the SDF-1/CXCR4 axis using CXCR4 blocking antibody blocked the recruitment of 
bone marrow-derived cells into the angiogenic sites of tumor tissue, and resulted in complete 
inhibition of accelerated tumor growth after chemotherapy in mouse [78]. SDF-1 is constitu-
tively expressed in the bone marrow and various tissues, which enables it to regulate the traf-
ficking, localization, and function of immature and mature leukocytes, including monocytes, 
neutrophils, dendritic cells, and T lymphocytes [79]. All these immune cells play an important 
role in tumor angiogenesis and vascularization. However, the precise role of SDF-1/CXCR4 
axis on function of monocytes/macrophages, neutrophils, DC, T lymphocytes in the process 
of angiogenesis is still known and is worthy to be investigated.
4. SDF-1 as a key regulator of vessel development
Global mouse knockouts of SDF-1 (CXCL12) or of its receptor CXCR4 die shortly before birth 
with vascular deficiency in gut, kidney, and skin and with multiple hematopoietic and neural 
defects [80-82]. Disrupted CXCL12 signaling led to defective coronary vessel organization 
in mouse embryos. This signaling was connected to perfusion of the coronary arteries and 
respectively to embryo growth [31].
SDF-1–positive endothelium was found lining the newly formed intraluminal vessels in lob-
ular capillary hemangiomas [83], possibly these were sites of pillar formation. Wrag et al. 
demonstrated that transplantation of rat bone marrow-derived progenitor cells, positive for 
VEGFR1, and CXCR4, in ischemic hind limbs increased capillary density by an SDF-1–depen-
dent manner, but did not differentiate into vascular structures like endothelial cells or smooth 
muscle cells [84]. In our previous study, we observed upregulation of SDF-1 and CXCR4 after 
Notch inhibition being in association with intussusceptive angiogenesis. These chemokine 
factors are most probably essential for the recruitment of mononuclear cells, participating in 
the formation of pillars.
It is well known that blocking of SDF-1/CXCR4 axis results in prevention or delay of tumor 
recurrence after irradiation by inhibiting the recruitment of CD11b+ monocytes/macrophages 
that participate in tumor revascularization [85]. It was shown that CXCR4 is expressed on 
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eosinophils [86] and concentrations of SDF-1 correlates with eosinophil recruitment [87]. 
It is known that SDF-1/CXCR4 signaling has pivotal role in mast cell (MC) recruitment in 
tumor tissue [88] and that MC produce proangiogenic chemokines in response to SDF-1 [89]. 
CXCR4+ dendritic cells (DC) promote angiogenesis during embryo implantation in mice [90] 
and CXCR4 is known as a critical chemokine receptor for migration of plasmacytoid DC [91]. 
CXCR4 is expressed on both NK and NKT cells and regulates their migration in inflamed 
and tumor tissues in response to SDF-1 as well [92, 93]. SDF-1/CXCR4 signaling is important 
for migration and activation of T cells [94]. However, the role of SDF-1/CXCR4 signaling in T 
cell–mediated angiogenesis is unknown. B cells promote tumor progression through STAT-3 
regulated angiogenesis [95] and SDF-1/CXCR4 axis is essential for B-lymphocyte production 
[96] and maintenance of B-cell homeostasis [97].
SDF-1 is the key regulator for homing of stem and progenitor cells to the ischemic injury and 
its gradient is the major determinant of these cells’ recruitment. It has been shown that SDF-1 
expression levels are increased in ischemic cardiomyopathy and this was accompanied by the 
improvement of cardiac function. In addition, SDF-1 high circulation levels were detected in 
patients with heart failure. Using the ELISA method, Liu et al. [98] proved significantly higher 
circulating SDF-1 levels in HF patients (5101 ± 1977 pg/ml) compared to controls (1879 ± 1417 
pg/ml). Platelet-bound SDF-1 was correlated with acute coronary syndrome and congestive 
heart failure as well. It was associated with the number of circulating CD34+ progenitor cells. 
CD34 is coexpressed with CXCR4, which is the ultimate SDF-1 receptor, in progenitor cells, 
originated from bone marrow, cord blood, and fetal liver. SDF-1 levels were measured in 3359 
Framingham Heart Study participants and was suggested as a biomarker of heart failure and 
all-cause mortality risk. In this study, CD34+ cell frequency was inversely related to SDF-1, 
in contrast to above-mentioned direct associations. The study has several limitations as the 
SDF-1 measurement at one time point. There is evidence for modulation of SDF-1 levels in 
humans and its effect is rather cumulative and chronic than acute.
The crucial role of SDF-1 for cardiac repair in chronic ischemic heart failure was the rea-
son for conducting clinical trial using SDF-1 nonviral gene therapy via its endomyocar-
dial administration [99]. This blinded placebo-controlled STOP-HF trial demonstrated 
improvement of clinical status based on composite endpoint of six MWD (6-min walk dis-
tance) and MLWHFQ (Minnesota Living with Heart Failure Quality of life Questionnaire). 
Another clinical trial–MARVEL was announced in 2015 to advance into US FDA Phase 3 
clinical evaluation of regenerative/cellular therapy of chronic heart failure, planned to be 
combined with SDF-1.
What trigger the SDF-1 upregulation is still elusive. Some authors postulate it is induced 
by HIF1α in response to hypoxia. However, other mechanisms of induction are also pos-
sible such as inflammation and subsequent release of mediators like interleukin-1 or tumor 
necrosis factor-α into circulation. It is evident by its induction not only in ischemic, but also in 
nonischemic cardiomyopathy. SDF-1 circulating levels were not influenced by the local heart 
hypoxia, but showed positive correlation with CRP, which is a marker for inflammation.
Recently, we have demonstrated the endothelial expression of SDF-1 in liver of Notch1 knockout 
mouse, whereby it was associated with intussusception (Figure 2).
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Connecting our observations for SDF-1 positivity and mononuclear cells (MNCs) partici-
pation in intussusceptive angiogenesis, we hypothesize that both processes are involved 
in vessel remodeling. Using our model of chicken area vasculosa, we performed detailed 
ultrastructural vessel study after application of recombinant SDF-1. A specific behavior of 
mononuclear cells was detected during this experiment. They were involved in a step-wise 
process of recruitment and extravasation (Figure 3). We determined five distinguished states: 
1, MNCs are free in the circulation; 2, MNCs are recruited to the endothelium and rolling 
under the blood flow; 3, MNCs are bound to the endothelium; 4, MNCs are extravasating; 5, 
MNCs are localized in the perivascular space.
1. MC free in circulation–nonadhesive to endothelial cells
2. MC tethered to endothelium and rolling under force of blood flow
3. MC bound to endothelium and migrating
4. Extravasation of MC from blood vessel
5. MC in perivascular space–stabilizing function
Figure 2. Vascular casts revealed predominant mode of intussusceptive angiogenesis in liver nodular regeneration after 
Notch1 knockout (B) compared to wild type mouse (A). Immunofluorescence for SDF-1 demonstrated strong sinusoidal 
positivity for this marker only in Notch1 knockout mouse (D) but not in the wild type (C).
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5. Summary
• Angiogenesis is a complex process involving essential signaling pathways (for instance 
VEGF, bFGF, Notch, etc.) in vasculature, as well as additional players such as bone mar-
row-derived mononuclear cells.
• Intussusceptive angiogenesis (IA) is a well-documented and widely spread mode of angio-
genesis, occurring both during normal development and in pathological conditions.
Figure 3. Transmission electron microscopy of chicken area vasculosa after the application of recombinant SDF-1 and the 
proposed model for mononuclear cells (MC) extravasation.
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• Our preliminary results suggest that IA is most probably synchronized by chemokine fac-
tors since intussusceptive growth was associated with the recruitment of mononuclear 
cells.
• The intensive studies in the past few years allowed distinguishing subpopulations of 
mononuclear cells existing in the adult bone marrow and circulating in peripheral blood 
which support angiogenesis.
• During endothelial repair after vascular injury and during tumor angiogenesis mononu-
clear cells do not seem to be involved in reendothelialization stressing rather their support-
ive role over trans-differentiation.
• We have demonstrated the endothelial expression of SDF-1 in liver of Notch1 knockout 
mouse, whereby it was associated with intussusceptive angiogenesis.
• We suggest that this chemokine factor is most probably essential for the recruitment of 
mononuclear cells, participating in step-wise process of extravasation and stabilizing the 
formation of intussusceptive pillars.
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